IQV
Iqvia Holdings Inc
NYSE · Life Sciences Tools & Services
$187.49
+6.53 (+3.61%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 16.01B | 15.36B | 16.26B | 16.41B | 12.85B |
| Net Income | 1.33B | 1.15B | 1.52B | 1.71B | 1.05B |
| EPS | — | — | — | — | — |
| Profit Margin | 8.3% | 7.9% | 9.4% | 10.4% | 8.2% |
| Rev Growth | +4.2% | +4.2% | -5.4% | -4.8% | -8.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 11.29B | 11.29B | 12.09B | 12.85B | 14.01B |
| Total Equity | 4.67B | 4.67B | 17.80B | 15.35B | 15.53B |
| D/E Ratio | 2.42 | 2.42 | 0.68 | 0.84 | 0.90 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 3.36B | 3.06B | 2.12B | 2.36B | 1.78B |
| Free Cash Flow | — | — | 1.53B | 1.51B | 1.28B |